Combination Therapy With Infliximab and Methotrexate in Recalcitrant Mucocutaneous Behçet Disease

Behçet disease is a multisystem inflammatory dis­ease with features of vasculitis. It undergoes peri­ods of spontaneous remission and relapse. It often affects the skin, blood vessels, central nervous system, joints, gastrointestinal system, eyes, mucous membrane, and other systems, and it can cause substantial morbidity and mortality. The etiology of Behçet disease remains unknown. Current treatment of Behçet disease involves symptomatic relief with prevention of relapse.

We describe the treatment of a recalcitrant case of Behçet disease with infliximab and metho­trexate. The patient is a 40-year-old Korean woman with tender lesions on the lower extremities of 1.5 years’ duration and intermittent oral and genital ulcerations that failed multiple conventional thera­pies. The patient was placed on a trial of infliximab. She reported resolution of the tender lower extremity lesions and the oral and vaginal ulcerations shortly after the initiation of the anti–tumor necrosis factor agent. The patient was symptom free for 2 years fol­lowing the initiation of infliximab. She subsequently reported mild breakthrough oral ulcers and joint pain. The treatment regimen was modified by adding methotrexate 7.5 mg weekly, prednisone 5 mg daily, and a shortened treatment interval of infliximab infu­sion that resulted in resolution of her symptoms.